|
EP0814790B1
(en)
*
|
1995-02-24 |
2003-07-16 |
Stuart L. Weg |
Administration of ketamine for detoxification
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
CA2529857A1
(en)
|
2002-07-30 |
2004-02-05 |
Peter Migaly |
Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
JP2006510618A
(ja)
*
|
2002-11-18 |
2006-03-30 |
ヤウポン セラピューティクス，インコーポレーテッド |
ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
PL377896A1
(pl)
|
2003-02-26 |
2006-02-20 |
Johns Hopkins University |
Związki modulujące transport glutaminianu i sposoby modulowania transportu glutaminianu
|
|
US20050038062A1
(en)
|
2003-04-14 |
2005-02-17 |
Burns Lindsay H. |
Methods and materials for the treatment of pain comprising opioid antagonists
|
|
CA2563707A1
(en)
|
2004-04-20 |
2005-11-03 |
Pfizer Inc. |
Method of treating neuropathic pain using a crth2 receptor antagonsit
|
|
US20060240043A1
(en)
|
2004-10-08 |
2006-10-26 |
Meyerson Laurence R |
Methods and compositions for treating migraine pain
|
|
WO2006069293A2
(en)
|
2004-12-22 |
2006-06-29 |
Friedman Robert S |
Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
|
|
AU2006219643A1
(en)
|
2005-03-01 |
2006-09-08 |
Pfizer Limited |
Use of PDE7 inhibitors for the treatment of neuropathic pain
|
|
CN101155548A
(zh)
|
2005-03-04 |
2008-04-02 |
曼提斯库拉Ehf.公司 |
评估神经病症的方法和系统
|
|
EP1874282B1
(en)
|
2005-04-06 |
2010-09-15 |
Adamas Pharmaceuticals, Inc. |
Methods and compositions for treatment of cns disorders
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
JP2009520040A
(ja)
|
2005-12-19 |
2009-05-21 |
ファーマイン コーポレーション |
治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
|
|
CN101466364A
(zh)
|
2006-03-22 |
2009-06-24 |
纽约大学西奈山医学院 |
鼻内施用氯胺酮治疗抑郁症
|
|
AU2007253684A1
(en)
|
2006-05-22 |
2007-11-29 |
Vanda Pharmaceuticals, Inc. |
Treatment for depressive disorders
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
WO2009014770A2
(en)
|
2007-02-01 |
2009-01-29 |
Green Alan I |
Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
WO2008140859A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
|
WO2008141057A1
(en)
|
2007-05-08 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
EP2175886A1
(en)
|
2007-06-28 |
2010-04-21 |
CNSBio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
|
CA2698038A1
(en)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Systems and methods for delivering drugs
|
|
EP2184986A4
(en)
|
2007-08-06 |
2010-12-15 |
Trinity Lab Inc |
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC PAIN AND PAIN RELATING TO NEUROPATHY
|
|
CA2700331A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
Co-administration of pimavanserin with other agents
|
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
CN102933207B
(zh)
|
2009-10-30 |
2018-02-02 |
Ix生物医药有限公司 |
快速溶解固体剂型
|
|
EP3579246A1
(en)
|
2010-01-18 |
2019-12-11 |
Elminda Ltd. |
Method and system for weighted analysis of neurophysiological data
|
|
WO2013003669A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
JP2015501652A
(ja)
|
2011-12-14 |
2015-01-19 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｇａｂｒ−ａ２診断
|
|
MX2014010939A
(es)
*
|
2012-03-12 |
2014-11-13 |
Janssen Pharmaceutica Nv |
Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento.
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
US20140079740A1
(en)
|
2012-08-02 |
2014-03-20 |
ClinPharm Support GmbH |
Oral transmucosal adminstration forms of s-ketamine
|
|
MX2015002378A
(es)
|
2012-08-23 |
2015-09-25 |
Stuart L Weg |
Composicion ansiolitica, formulacion y metodo de uso.
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
WO2014100501A1
(en)
|
2012-12-20 |
2014-06-26 |
Sanford-Burnham Medical Research Institute |
Small molecule agonists of neurotensin receptor 1
|
|
WO2014152196A1
(en)
|
2013-03-15 |
2014-09-25 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
EP3498268A1
(en)
|
2013-03-15 |
2019-06-19 |
Janssen Pharmaceutica NV |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
MX2015013845A
(es)
*
|
2013-04-01 |
2016-05-09 |
Pulmatrix Inc |
Polvos secos de tiotropio.
|
|
EP3960162A1
(en)
|
2013-08-26 |
2022-03-02 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
ES2897453T3
(es)
|
2013-09-13 |
2022-03-01 |
Univ Chiba Nat Univ Corp |
Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
|
|
EP3094312B1
(en)
|
2014-01-14 |
2019-03-13 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
ES2829279T3
(es)
|
2014-04-17 |
2021-05-31 |
Develco Pharma Schweiz Ag |
Forma de dosificación oral de ketamina
|
|
RU2721948C2
(ru)
|
2014-05-06 |
2020-05-25 |
Нортвестерн Юниверсити |
Комбинации соединений, модулирующих nmda-рецептор
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
WO2016025581A1
(en)
|
2014-08-13 |
2016-02-18 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
|
AU2015318123A1
(en)
|
2014-09-15 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
CA2963085C
(en)
*
|
2014-10-07 |
2023-02-21 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
SI3215147T1
(sl)
|
2014-11-04 |
2024-05-31 |
Acadia Pharmaceuticals Inc. |
Nevroatenuacijske spojine norketamina in postopki
|
|
WO2016094358A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
EP3240422A1
(en)
|
2014-12-31 |
2017-11-08 |
Icahn School of Medicine at Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
|
WO2016112467A1
(en)
|
2015-01-15 |
2016-07-21 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
*
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
CN108291259A
(zh)
|
2015-06-12 |
2018-07-17 |
印第安纳大学研究与技术公司 |
使用组合的基因组和临床风险评估预测自杀倾向
|
|
US11191734B2
(en)
|
2015-06-27 |
2021-12-07 |
Shenox Pharmaceuticals, Llc |
Ketamine transdermal delivery system
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
CA3002070A1
(en)
|
2015-10-16 |
2017-04-20 |
Northwestern University |
Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
US11110070B2
(en)
|
2015-11-17 |
2021-09-07 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
CA3019012A1
(en)
|
2016-03-25 |
2017-09-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
TWI648049B
(zh)
|
2016-05-25 |
2019-01-21 |
National Health Research Institutes |
用於減低ｋ他命之致精神病狀副作用及成癮疾患的方法與組成物
|
|
KR102661616B1
(ko)
|
2016-07-28 |
2024-04-30 |
리제너론 파마슈티칼스 인코포레이티드 |
Gpr156 변이체 및 이들의 용도
|
|
WO2018025089A2
(en)
|
2016-08-05 |
2018-02-08 |
Shin Nippon Biomedical Laboratories, Ltd. |
Pharmaceutical compositions
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
AU2017351437B2
(en)
|
2016-10-27 |
2022-01-27 |
National University Corporation Chiba University |
Application of (S)-norketamine and salt thereof as pharmaceutical
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
US20200030251A1
(en)
|
2017-04-20 |
2020-01-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
WO2018209341A1
(en)
|
2017-05-12 |
2018-11-15 |
Indiana University Research And Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
JP7312116B2
(ja)
|
2017-05-25 |
2023-07-20 |
グリテック， エルエルシー |
外傷後ストレス障害の治療用の製剤
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
EP3641742A2
(en)
|
2017-06-23 |
2020-04-29 |
Develco Pharma Schweiz AG |
Hydroxynorketamine for the use in the treatment of depression
|
|
AU2018319592B2
(en)
|
2017-08-20 |
2024-06-27 |
Nasus Pharma Ltd. |
Dry powder compositions for intranasal delivery
|
|
US20210315840A1
(en)
|
2017-09-25 |
2021-10-14 |
Small Pharma Ltd |
Solid oral dosage forms of ketamine derivatives
|
|
US20200405663A1
(en)
|
2017-09-27 |
2020-12-31 |
National University Corporation Chiba University |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
CA3079560A1
(en)
|
2017-10-19 |
2019-04-25 |
Eleusis Benefit Corporation, Pbc |
Methods and systems for enhancing safety of psychedelic drug therapies
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
EP3710079A4
(en)
|
2017-11-14 |
2021-09-01 |
Bexson Biomedical, Inc. |
SYSTEMS, DEVICES, FORMULATIONS AND PROCEDURES FOR CONTROLLED INGREDIENT DELIVERY
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
CA3086478A1
(en)
|
2017-12-22 |
2019-06-27 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of depression
|
|
PT3505157T
(pt)
|
2017-12-29 |
2022-02-18 |
Celon Pharma Sa |
Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
|
|
CN111836798B
(zh)
|
2018-01-10 |
2022-04-15 |
凯瑞康宁生物工程（武汉）有限公司 |
氯胺酮的前药、其组合物和用途
|
|
EP3755332A1
(en)
|
2018-02-21 |
2020-12-30 |
AI Therapeutics, Inc. |
Combination therapy with apilimod and glutamatergic agents
|
|
US11980617B2
(en)
|
2018-03-16 |
2024-05-14 |
Intra-Cellular Therapies, Inc. |
Methods of treating acute depression and/or acute anxiety
|
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
EP3813808A4
(en)
|
2018-05-04 |
2022-01-26 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
WO2019227169A1
(en)
|
2018-05-31 |
2019-12-05 |
The University Of Queensland |
Core-shell polymer nanoparticle
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
EP3813802B1
(en)
|
2018-06-27 |
2024-10-23 |
Bioxcel Therapeutics, Inc. |
Film formulations containing dexmedetomidine and methods of producing them
|
|
US12036189B2
(en)
|
2018-06-27 |
2024-07-16 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
WO2020028475A1
(en)
|
2018-08-02 |
2020-02-06 |
Taiwan Liposome Co., Ltd. |
Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
EP3628313B1
(en)
*
|
2018-09-28 |
2025-02-12 |
Novohale Therapeutics, LLC |
Ketamine composition for use in a method of treatment of depression by pulmonary administration
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
US20210308040A1
(en)
|
2018-10-26 |
2021-10-07 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
WO2020089897A1
(en)
|
2018-10-29 |
2020-05-07 |
Hadasit Medical Research Services & Development Limited |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
CN113395962A
(zh)
|
2018-11-21 |
2021-09-14 |
Certego治疗公司 |
加波沙朵用于降低自杀风险和快速缓解抑郁症
|
|
CN113423686B
(zh)
|
2019-01-11 |
2023-08-22 |
昱展新药生技股份有限公司 |
氯胺酮双羟萘酸盐及其用途
|
|
WO2020154362A1
(en)
|
2019-01-23 |
2020-07-30 |
The Regent Of The University Of Michigan |
Pharmacogenomic decision support for modulators of the nmda, glycine, and ampa receptors
|
|
US20200261422A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
IL318198A
(en)
|
2019-03-05 |
2025-03-01 |
Janssen Pharmaceuticals Inc |
Esketamine for the treatment of depression
|
|
EP4219498A1
(en)
|
2019-03-07 |
2023-08-02 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
|
|
WO2020190997A1
(en)
|
2019-03-18 |
2020-09-24 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
KR20210153667A
(ko)
|
2019-04-17 |
2021-12-17 |
에르테에스 로만 테라피-시스테메 아게 |
경피 치료 시스템
|
|
US20220313650A1
(en)
|
2019-05-02 |
2022-10-06 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
US20220202742A1
(en)
|
2019-05-07 |
2022-06-30 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
WO2020239243A1
(en)
|
2019-05-31 |
2020-12-03 |
Celon Pharma S.A. |
Electronically supervised administration of a pharmaceutical composition
|
|
BR112021024141A2
(pt)
|
2019-05-31 |
2022-01-11 |
Celon Pharma Sa |
Inalador para administração parenteral supervisionada eletronicamente de uma composição farmacêutica
|
|
US20220257536A1
(en)
|
2019-06-04 |
2022-08-18 |
ADNP Kids Research Foundation |
Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
|
|
CA3133012A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
EP4021432A4
(en)
|
2019-08-28 |
2023-08-16 |
Janssen Pharmaceuticals, Inc. |
ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
US20220339123A1
(en)
|
2019-09-13 |
2022-10-27 |
Janssen Pharmaceuticals, Inc. |
Intranasal administration of esketamine
|
|
CN114727989A
(zh)
|
2019-10-02 |
2022-07-08 |
普拉西斯精密医药公司 |
Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合
|
|
US20230095907A1
(en)
|
2019-10-18 |
2023-03-30 |
Institute Of Science And Technology Austria |
Stimulation of neuronal plasticity
|
|
WO2021087258A1
(en)
|
2019-10-31 |
2021-05-06 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
WO2021108801A2
(en)
|
2019-11-15 |
2021-06-03 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
WO2021101867A1
(en)
|
2019-11-18 |
2021-05-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same
|
|
US11660305B2
(en)
|
2019-11-19 |
2023-05-30 |
Turtle Bear Holdings, Llc |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
CA3152593A1
(en)
|
2019-12-20 |
2021-06-24 |
Tong-Ho Lin |
Long-acting injectable formulations of ketamine pamoate salts
|
|
JP2023507926A
(ja)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
|
|
IL293506A
(en)
|
2019-12-30 |
2022-08-01 |
Clexio Biosciences Ltd |
Dosage regime with esketamine for treating major depressive disorder
|
|
TW202139981A
(zh)
|
2020-01-22 |
2021-11-01 |
美商西羅斯醫療公司 |
降低nmda拮抗劑之副作用
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
WO2021207349A1
(en)
|
2020-04-07 |
2021-10-14 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
AU2021275863A1
(en)
|
2020-05-20 |
2023-02-02 |
Certego Therapeutics Inc. |
Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
|
|
US20230210789A1
(en)
|
2020-06-02 |
2023-07-06 |
Ix Biopharma Limited |
Methods for treating major depressive disorder and treatment-resistant depression
|
|
TW202214218A
(zh)
|
2020-06-19 |
2022-04-16 |
大陸商廣州大洲生物醫藥科技有限公司 |
氯胺酮的透皮給藥系統
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
AU2021329820A1
(en)
|
2020-08-18 |
2023-03-09 |
Oakwood Laboratories, Llc |
Microsphere formulations comprising ketamine and methods for making and using the same
|
|
WO2022081350A2
(en)
|
2020-09-30 |
2022-04-21 |
Duke University |
Methods for identification, stratification, and treatment of cns diseases
|
|
EP3995137B1
(de)
|
2020-11-09 |
2024-01-03 |
LTS Lohmann Therapie-Systeme AG |
Oraler dünnfilm
|
|
EP4247259A4
(en)
|
2020-11-18 |
2024-10-16 |
Indiana University Research and Technology Corporation |
METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, ADAPTATION TO EXISTING MEDICATIONS AND NEW MEDICATION USE METHODS AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
TWI844074B
(zh)
|
2021-08-13 |
2024-06-01 |
凱瑞康寧生技股份有限公司 |
氯胺酮衍生物之醫藥組成物及口服劑型
|
|
US20230144704A1
(en)
|
2021-11-05 |
2023-05-11 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
WO2024010935A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|